Liraglutide Safely Lowers Cardiovascular Risk By 13 Percent In Patients With Type 2 Diabetes After almost four years of clinical trials, a study on liraglutide has finally concluded. Results showed that the injectable drug can reduce cardiovascular risk by 13 percent in patients with type 2 diabetes, without any serious adverse effects. by Catherine Cabral-Isabedra
Xi Jinping Warns Against Chip Restrictions During Talks with Dutch PM Rutte: 'No Force Can Stop China's Progress'
Researchers Achieve Record Data Transmission Speed, 4.5 Million Times Faster Than Average Home Broadband